BioCentury | Aug 20, 2020
Politics, Policy & Law

Updated plan for China’s reimbursement increases pricing pressure on checkpoint inhibitors

...citing the eligibility of anti-PD-1 antibody camrelizumab (SHR-1210...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

...inhibitor first for HCC in China China’s National Medical Products Administration (NMPA) has approved camrelizumab (SHR-1210...
...Programmed cell death 1 ligand 1 VEGF - Vascular endothelial growth factor BioCentury Staff Camrelizumab (INCSHR1210, SHR-1210) NIH AstraZeneca...
BioCentury | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

...company since 1995. Hengrui markets a variety of drugs including classical Hodgkin lymphoma therapy camrelizumab (SHR-1210...
BioCentury | Jan 7, 2020
Company News

BeiGene looks to carve out niche in China for tislelizumab

...made it at least the third PD-1 inhibitor approved for classical Hodgkin lymphoma after camrelizumab (SHR-1210...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...patients 6-17 years of age Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:3600276) China's NMPA approves camrelizumab (SHR-1210...
BioCentury | May 31, 2019
Company News

May 31 Company Quick Takes: NMPA accepts two BeiGene applications, approves Hengrui's PD-1 inhibitor; and more

...from Celgene Corp. (NASDAQ:CELG). Hengrui PD-1 inhibitor approved for Hodgkin lymphoma NMPA has approved camrelizumab (SHR-1210...
...approved in the indication for patients ineligible for ASCT. Jonathan Block, Associate Editor Abraxane, nab-paclitaxel (ABI-007) Camrelizumab (INCSHR1210, SHR-1210) Darzalex...
BioCentury | Dec 27, 2018
Company News

China’s NMPA approves Innovent’s PD-1 mAb Tyvyt for Hodgkin lymphoma

...Hodgkin lymphoma are under NMPA review: tislelizumab (BGB-A317) from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) and camrelizumab (SHR-1210...
...news after market close in Hong Kong Thursday, gained HK$1.10 to HK$22.30 Friday. Allison Johnson Camrelizumab (INCSHR1210, SHR-1210) sintilimab...
BioCentury | Dec 21, 2018
Clinical News

China approves Junshi’s Tuoyi, first domestic anti-PD-1 mAb

...sintilimab from Innovent Biologics Inc. (HKSE:1801), tislelizumab (BGB-A317) from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) and camrelizumab (SHR-1210...
BioCentury | Dec 17, 2018
Company News

China approves Junshi’s Tuoyi, first domestic anti-PD-1 mAb

...sintilimab from Innovent Biologics Inc. (HKSE:1801), tislelizumab (BGB-A317) from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) and camrelizumab (SHR-1210...
BioCentury | Jun 22, 2018
Clinical News

BMS first to cross finish line in China PD-1 approval race

...under Priority Review in China: sintilimab (IBI308) from Innovent Biologics Inc. (Suzhou, China); and camrelizumab (SHR-1210...
...Ltd. (Shanghai:3600276). Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Opdivo nivolumab Business: Cancer Allison Johnson INCSHR1210, SHR-1210 Keytruda...
Items per page:
1 - 10 of 16